RxDoctor Payments Data

Jessica Dlugolecki

Family · Chittenango, NYNPI 1841867603

Payments from drug & device makers

$837in general payments, 2019–2025

Across 45 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$220
  • AstraZeneca$119
  • Lilly USA, LLC$63
  • Boehringer Ingelheim$57
  • Pfizer$56
  • GSK$49
  • plus $273 from 11 others

What the payments were for

  • Food & beverage$837100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$837 in reported general payments places this provider in the 70th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$9,238
Medicare patients
45
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DescovyEmtricitabine/Tenofov Alafenam14$35,767
MounjaroTirzepatide27$32,015
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$19,278
RybelsusSemaglutide11$17,244
TrulicityDulaglutide14$15,295
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$5,351
Incruse ElliptaUmeclidinium Bromide12$3,848
Albuterol Sulfate HfaAlbuterol Sulfate69$2,516
Levothyroxine Sodium49$503
Ondansetron OdtOndansetron12$490
Omeprazole43$444
Gabapentin38$430
Atorvastatin Calcium42$365
Cyclobenzaprine Hcl15$359
Lisinopril34$309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$63$47,31041 claims
GSKTrelegy Ellipta, Incruse Ellipta$49$23,12640 claims
Novo NordiskRybelsus$220$17,24411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,883 family providers in New York.

Other family in Chittenango

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →